CALIFORNIA — The court overturned a state appeals court ruling from two years prior that held Gilead could be liable. This reversal ends the immediate legal threat posed by the lower court's previous judgment against the American biopharmaceutical company.

More than 24,000 people filed lawsuits in federal and state courts claiming they suffered kidney injury and bone loss from an older drug sold by Gilead. These plaintiffs argued that Gilead was negligent for delaying the development of an HIV medicine that was safer than another drug the company was already selling.

Gilead Sciences was established in 1987. The California Supreme Court serves as the highest court of the U.S. state of California.

The ruling resolves a significant portion of litigation involving more than 24,000 claimants who alleged physical harm from the company's products. By overturning the liability finding from two years prior, the state's highest court rejected the argument that the delay in developing a safer alternative constituted negligence under the presented legal framework. This decision affects the scope of duty pharmaceutical companies may owe regarding the timing of new drug development relative to existing products.

Why It Matters

This ruling resolves a significant portion of litigation involving more than 24,000 claimants who alleged physical harm from the company's products. By overturning the liability finding from two years prior, the state's highest court rejected the argument that the delay in developing a safer alternative constituted negligence under the presented legal framework. This decision affects the scope of duty pharmaceutical companies may owe regarding the timing of new drug development relative to existing products.